MCRPC
Clinical trials for MCRPC explained in plain language.
Never miss a new study
Get alerted when new MCRPC trials appear
Sign up with your email to follow new studies for MCRPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo may stall aggressive prostate cancer
Disease control OngoingThis study tests whether adding talazoparib to standard enzalutamide treatment helps men with metastatic castration-resistant prostate cancer (mCRPC) live longer without their cancer getting worse. About 1,054 men took part. The goal is to see if the combination slows tumor growt…
Matched conditions: MCRPC
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 17, 2026 07:36 UTC
-
Promising prostate cancer drug extended to patients already improving
Disease control ENROLLING_BY_INVITATIONThis study gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694 if they are already benefiting from it in an earlier trial. About 40 participants will receive the drug for up to two more weeks after their previ…
Matched conditions: MCRPC
Phase: PHASE1, PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New antibody cocktail targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC). Seven men with advanced disease that has stopped responding to standard hormone therapy will receive the combinati…
Matched conditions: MCRPC
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 14, 2026 12:04 UTC